Abstract
The ability to tailor the release profile of a drug by manipulating its formulation matrix offers important therapeutic advantages. We show here that human insulin can be cocrystallized at preselected ratios with the fully active lipophilically modified insulin derivative octanoyl-Nε-LysB29–human insulin (C8-HI). The cocrystal is analogous to the NPH (neutral protamine Hagedorn) crystalline complex formed with human insulin, which is commonly used as the long-acting insulin component of diabetes therapy. The in vitro and in vivo release rates of the cocrystal can be controlled by adjusting the relative proportions of the two insulin components. We identified a cocrystal composition comprising 75% C8-HI and 25% human insulin that exhibits near-ideal basal pharmacodynamics in somatostatin-treated beagle dogs. The dependence of release rate on cocrystal ratio provides a robust mechanism for modulating insulin pharmacodynamics. These findings show that a crystalline protein matrix may accommodate a chemical modification that alters the dissolution rate of the crystal in a therapeutically useful way, yet that is structurally innocuous enough to preserve the pharmaceutical integrity of the original microcrystalline entity and the pharmacological activity of the parent molecule.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Langer, R. New methods of drug delivery. Science 249, 1527–1532 (1990).
Putney, S.D. & Burke, P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16, 153–157 (1998).
Banerjee, P.S., Hosny, E.A. & Robinson, J.R. Parenteral delivery of peptide and protein drugs. in Peptide and Protein Delivery, Vol. 4 (ed. Lee, V.H.L.) 487–543 (Marcel Dekker, Los Angeles, 1991).
Shah, V.P., Skelly, J.P., Barr, W.H., Malinowski, H. & Amidon, G. Scale-up of controlled release products—preliminary considerations. Pharm. Technol. 5, 35–40 (1992).
Hagedorn, H.C., Jensen, B.N., Krarup, N.B. & Wodstrup, I. Protamine insulinate. JAMA 106, 177–180 (1936).
Felig, P. Hagedorn's pioneering contribution to drug delivery in the management of diabetes. JAMA 251, 393–396 (1984).
Krayenbühl, C. & Rosenberg, T. Crystalline protamine insulin. Rep. Steno. Mem. Hosp. Nord. Insulinlab 1, 60–73 (1946).
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).
Ohkubo, Y. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized, prospective 6-year study. Diabetes Res. Clin. Pract. 28, 103–117 (1995).
Galloway, J.A. & Chance, R.E. Improving insulin therapy: achievements and challenges. Horm. Met. Res. 26, 591–598 (1994).
Owens, D.R., Zinman, B. & Bolli, G.B. Insulins today and beyond. Lancet 358, 739–746 (2001).
DeFelippis, M.R. et al. Preparation and characterization of a cocrystalline suspension of [LysB28,-ProB29]-human insulin analog. J. Pharm. Sci. 87, 170–176 (1998).
Baker, E.N. et al. The structure of 2Zn pig insulin crystals at 1.5Å resolution. Philos. Trans. R. Soc. Lond. B 319, 369–456 (1988).
Balschmidt, P., Benned-Hansen, F., Dodson, E.J., Dodson, G.G. & Korber, F. Structure of porcine insulin cocrystallized with clupeine-Z. Acta Crystallogr. B47, 975–986 (1991).
Brader, M.L. et al. Effects of surface hydrophobicity on the structural properties of insulin. in Techniques in Protein Chemistry VIII (ed. Marshak, D.R.) 289–297 (Academic Press, San Diego, CA, 1997).
Whittingham, J.L., Havelund, S. & Jonassen, I. Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry 36, 2826–2831 (1997).
Markussen, J. et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281–288 (1996).
Myers, S.R. et al. Acylation of human insulin with palmitic acid extends the time-action of human insulin in diabetic dogs. Diabetes 46, 637–642 (1997).
Hamilton-Wessler, M. et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 42, 1254–1263 (1999).
Radziuk, J. et al. Basal activity profiles of NPH and [Nε-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia 41, 116–120 (1998) [erratum (1998) 41, 489].
Heinemann, L. et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabetes Med. 16, 332–338 (1999).
Kurtzhals, P. et al. Albumin-binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312, 725–731 (1995).
Katsoyannis, P.G. The chemical synthesis of insulin and the pursuit of structure-activity relationships. in Structural Studies on Molecules of Biological Interest (eds. Dodson, G.G., Glusker, J.P. & Sayre, D.) 454–486 (Clarendon Press, Oxford, 1981).
Abel, J.J. Crystalline insulin. Proc. Natl. Acad. Sci. USA 12, 132–135 (1926).
Baker, E.N. & Dodson, G.G. X-ray diffraction data on some crystalline varieties of insulin. J. Mol. Biol. 54, 605–609 (1970).
Whittingham, J.L., Chaudhuri, S., Dodson, E.J., Moody, P.C.E. & Dodson, G.G. X-ray crystallographic studies on some hexameric insulins in the presence of helix-stabilizing agents, thiocyanate, methylparaben, and phenol. Biochemistry 34, 15553–15563 (1995).
Derewenda, U. et al. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature 338, 594–596 (1989).
Brange, J et al. Galenics of Insulin (Springer, Berlin Heidelberg, 1987).
DeFelippis, M.R. & Akers, M.J. Peptides and proteins as parenteral suspensions: an overview of design, development, and manufacturing considerations. in Pharmaceutical Formulation Development of Peptides and Proteins (eds Frokjaer, S. & Hovgaard, L.) 113–144 (Taylor and Francis, Philadelphia, 2000).
MacPherson, A. Crystallization of Biological Macromolecules (Cold Spring Harbor Laboratory Press, New York, 1999).
Brems, D.N. et al. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5, 527–533 (1992).
Yip, C.M., DeFelippis, M.R., Frank, B.F., Brader, M.L. & Ward, M.D. Structural and morphological characterization of ultralente insulin crystals by atomic force microscopy: evidence of hydrophobically driven assembly. Biophys. J. 75, 1172–1179 (1998).
Ribel, U., Jørgensen, K., Brange, J. & Henriksen, U. The pig as a model for subcutaneous insulin absorption in man. in Diabetes (eds Serrano-Rios, M. & Lefebvre, P.J.) 891–896 (Elsevier Science, Amsterdam, 1985).
Steiner, D.F. Cocrystallization of proinsulin with insulin. Nature 243, 528–530 (1973).
Hassiepen, U., Federwisch, M., Mülders, T. & Wollmer, A. The lifetime of insulin hexamers. Biophys. J. 77, 1638–1654 (1999).
Jen, A. & Merkle, H.P. Diamonds in the rough: protein crystals from a formulation perspective. Pharm. Res. 18, 1483–1488 (2001).
Stevens, R.C. High-throughput protein crystallization. Curr. Opin. Struct. Biol. 10, 558–563 (2000).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors are employees of Eli Lilly and Company, which manufactures and sells insulin.
Rights and permissions
About this article
Cite this article
Brader, M., Sukumar, M., Pekar, A. et al. Hybrid insulin cocrystals for controlled release delivery. Nat Biotechnol 20, 800–804 (2002). https://doi.org/10.1038/nbt722
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt722
This article is cited by
-
Large-scale crystallization of proteins for purification and formulation
Bioprocess and Biosystems Engineering (2015)
-
Novel Long-Acting Crystal Formulation of Human Growth Hormone
Pharmaceutical Research (2005)
-
A crystal clear solution for insulin delivery
Nature Biotechnology (2002)
-
Engineering a smoother ride
Nature Reviews Drug Discovery (2002)